Search

Your search keyword '"Esther Ruiz-Lucea"' showing total 4 results
Start Over Author "Esther Ruiz-Lucea" Language english
4 results on '"Esther Ruiz-Lucea"'

1. Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry

Author

Tatiana Cobo-Ibáñez, Ivan Castellví, Ana Pros, Marta Domínguez-Álvaro, Laura Nuño-Nuño, Julia Martínez-Barrio, Vega Jovaní, Fredeswinda Romero-Bueno, Esther Ruiz-Lucea, Eva Tomero, Ernesto Trallero-Araguás, Javier Narváez, Jordi Camins-Fàbregas, Alberto Ruiz-Román, Jesús Loarce-Martos, Susana Holgado-Pérez, V Miguel Flores-Rodríguez, Francisca Sivera, Carolina Merino-Argumanez, Antonio Juan-Mas, Irene Altabás-González, María Martín-López, Joaquín María Belzunegui-Otano, Carmen Carrasco-Cubero, Mercedes Freire-González, Iñigo Rúa-Figueroa, Nuria Lozano-Rivas, Julio David Suarez-Cuba, Olga Martínez, Rafaela Ortega-Castro, Patricia Alcocer, Alejandro Gómez-Gómez, Olga Sánchez-Pernaute, José Luis Tandaipan, Irene Carrión-Barberà, Chamaida Plasencia-Rodríguez, Oihane Ibarguengoitia-Barrena, Paola Vidal-Montal, Vera Ortiz-Santamaria, Noemi Garrido-Puñal, Anne Riveros, Esmeralda Delgado-Frías, Juan Miguel López-Gómez, Carmen Barbadillo, José María Pego-Reigosa, Beatriz E. Joven-Ibáñez, Jesús Alejandro Valero-Jaimes, Elena Naveda, Ana Isabel Turrión-Nieves, Daniel Seoane-Mato, Francisco Javier Prado-Galbarro, and M Ángeles Puche-Larrubia

Subjects
Idiopathic inflammatory myopathies, Antisynthetase, Autoantibodies, Activity, Damage, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Objective To evaluate the main outcomes of disease activity and their association with other measures of activity, damage, and quality of life in patients with idiopathic inflammatory myopathy (IIM) according to time since diagnosis and positivity to antisynthetase autoantibodies (ASAs). Methods Cross-sectional multicenter study within the Spanish Myo-Spain registry. Cases were classified as incident (≤ 12 months since diagnosis) and prevalent. The main outcomes of disease activity were the Myositis Disease Activity Assessment visual analogue scale (MYOACT), the Manual Muscle Test 8 (MMT-8), physician global activity (PhGA), and extramuscular activity. Other measures of activity, damage, and quality of life included patient global disease activity, MYOACT muscular, creatine phosphokinase, Health Assessment Questionnaire, physician and patient global damage, global damage of the Myositis Damage Index, and the 12-item Short-Form Health Survey (SF-12). We analyzed associations using a multivariate generalized linear model and a simple linear regression model. Results A total of 554 patients with different diagnostic subgroups of IIM were included (136 incident and 418 prevalent cases), with 215 ASA-positive patients (58 incident and 157 prevalent cases). All measures of disease activity were higher in the incident cases (p

Published
2025
Full Text
View/download PDF

2. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

Author

Loreto Carmona, Carlos Montilla, Ricardo Blanco, Ana Pérez, Íñigo Rúa-Figueroa, Celia Erausquin, Beatriz Tejera Segura, Javier Narváez, Irene Carrión-Barberà, Jorge Juan Fragío Gil, Raúl Menor-Almagro, Antonio Fernández-Nebro, Eva Tomero, Esther Ruiz-Lucea, Julia Martínez-Barrio, Gema Bonilla, Elena Aurrecoechea, María Jesús García-Villanueva, Eva Salgado, Mercedes Freire-González, Jaime Calvo Alen, Tatiana Cobo, María Galindo Izquierdo, Mónica Ibáñez-Barcelo, Loreto Horcada, Lorena Expósito, Joan M Nolla, Alejandro Muñoz-Jiménez, Jose L Andreu, Clara Sanguesa, Nuria Lozano-Rivas, Marta Arévalo, Carlota Iniguez, M Jesus García de Yébenes, Esther Uriarte Itzazelaia, José Carlos Rosas Gómez de Salazar, Silvia Gómez-Sabater, Claudia Moriano Morales, Vicente Torrente Segarra, Javier Nóvoa Medina, Angela Pecondón, Francisco J Toyos, Jose Oller, and J M Pego-Reigosa

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Objective To develop an improved score for prediction of severe infection in patients with systemic lupus erythematosus (SLE), namely, the SLE Severe Infection Score-Revised (SLESIS-R) and to validate it in a large multicentre lupus cohort.Methods We used data from the prospective phase of RELESSER (RELESSER-PROS), the SLE register of the Spanish Society of Rheumatology. A multivariable logistic model was constructed taking into account the variables already forming the SLESIS score, plus all other potential predictors identified in a literature review. Performance was analysed using the C-statistic and the area under the receiver operating characteristic curve (AUROC). Internal validation was carried out using a 100-sample bootstrapping procedure. ORs were transformed into score items, and the AUROC was used to determine performance.Results A total of 1459 patients who had completed 1 year of follow-up were included in the development cohort (mean age, 49±13 years; 90% women). Twenty-five (1.7%) had experienced ≥1 severe infection. According to the adjusted multivariate model, severe infection could be predicted from four variables: age (years) ≥60, previous SLE-related hospitalisation, previous serious infection and glucocorticoid dose. A score was built from the best model, taking values from 0 to 17. The AUROC was 0.861 (0.777–0.946). The cut-off chosen was ≥6, which exhibited an accuracy of 85.9% and a positive likelihood ratio of 5.48.Conclusions SLESIS-R is an accurate and feasible instrument for predicting infections in patients with SLE. SLESIS-R could help to make informed decisions on the use of immunosuppressants and the implementation of preventive measures.

Published
2024
Full Text
View/download PDF

3. O17 SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus, developed from RELESSER prospective database cohort

Author

Loreto Carmona, Ricardo Blanco, Íñigo Rúa-Figueroa, Celia Erausquin, María Jesus García de Yébenes, José M Pego-Reigosa, Javier Narváez, Raúl Menor-Almagro, Jaime Calvo-Alén, Antonio Fernández-Nebro, Eva Tomero, Mercedes Freire, Esther Ruiz-Lucea, Julia Martínez-Barrio, María Galindo-Izquierdo, Clara Moriano, Elena Aurrecoechea, Jose Luis Andreu, Jose Rosas, Tatiana Cobo, Ángela Pecondón-Español, Loreto Horcada, Esther Uriarte Isacelaya, Lorena Expósito, Alejandro Muñoz-Jiménez, Irene Carrion Barbera, Beatriz García-Tejera, Clara Sanguesa, Silvia Gómez Sabater, Vicenç Torrente Segarra, Ana Pérez Gómez, Francisco J Nóvoa, Eva Salgado Pérez, Nuria Lozano-Rivas, Carlos Montilla-Morales, Marta Arévalo, Carlota Iniguez, Maria J García Villanueva, Monica Ibañez, Gema Bonilla Hernán, Jorge Fragío, Francisco Javier Toyos, and José Eloy Oller

Subjects
Immunologic diseases. Allergy, RC581-607
Published
2024
Full Text
View/download PDF

4. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology

Author

Ivan Castellví, Javier Narváez, Iñigo Rúa-Figueroa, Susana Holgado, Ernesto Trallero-Araguás, Nuria Lozano, Esmeralda Delgado-Frías, Carmen Barbadillo, Eva Tomero, Mónica Ibáñez, Rafaela Ortega-Castro, José M. Pego-Reigosa, Fredeswinda Romero-Bueno, Pilar Trenor Larra, Vega Jovani, Mercedes Freire, Alberto Ruiz-Román, Laura Nuño-Nuño, Ana Pérez Gómez, Beatriz Joven, Patricia Alcocer, Tatiana Cobo-Ibáñez, Jordi Camins, María Esther Ruiz-Lucea, Carmen Carrasco Cubero, Marina Rodríguez López, Francisca Sivera, Julia Martínez-Barrio, Irene Carrión-Barberà, J. Belzunegui, Olga Martínez-González, Carlos Sánchez-Piedra, Carmen Larena, and Alejandro Gómez Gómez

Subjects
Tratamiento médico, Dermatomiositis, Rheumatology, Miositis, Enfermedad, Registros de investigación
Abstract

Objetivos Describir la metodología del Registro de pacientes con miopatía inflamatoria idiopática (MII) de España (Myo-Spain), así como sus fortalezas y limitaciones. El objetivo principal del proyecto es analizar la evolución y el manejo clínico de una cohorte de pacientes con MII. Material y método Estudio observacional, longitudinal, ambispectivo y multicéntrico de una cohorte de pacientes con MII atendidos en servicios de reumatología de España. Se incluirán todos los pacientes con diagnóstico de MII en seguimiento habitual por los centros participantes, sin tener en cuenta la edad de inicio del proceso. Los casos incidentes serán todos los pacientes que al inicio del estudio en cada centro estén diagnosticados desde hace menos de 12 meses y casos prevalentes desde hace más de 12 meses. Se construirá un registro en el que se incluirán los datos de la visita basal, del año y dos años. Se recogerán variables sociodemográficas, clínicas, analíticas, complicaciones, comorbilidad, asociación con otras enfermedades reumáticas, ingresos hospitalarios, mortalidad y tratamientos. Además, se determinarán índices, escalas y cuestionarios de actividad, afectación muscular, daño, discapacidad y calidad de vida. El periodo de reclutamiento será de 23 meses. El propósito es conseguir una cohorte de 400 pacientes con MII. Conclusiones El estudio Myo-Spain constituye la oportunidad para desarrollar una cohorte de pacientes incidentes y prevalentes con MII en España. Myo-Spain permitirá evaluar en detalle, las características clínicas de la enfermedad en diferentes momentos. Se espera que la información exhaustiva recogida en las visitas suponga una amplia fuente de datos para futuros análisis. Objectives: To describe the methods of the Spanish Registry of patients with idiopathic inflammatory myopathy (IIM) (Myo-Spain), as well as its strengths and limitations. The main objective of the project is to analyse the evolution and clinical management of a cohort of patients with IIM. Methods: Observational, longitudinal, ambispective and multicentre study of a cohort of patients with IIM seen in rheumatology units in Spain. All patients with a diagnosis of IMM will be included in the regular follow-up of the participating centres, regardless of age on initiation of the process. Incident cases will be all patients who at the beginning of the study have been diagnosed for less than 12 months and prevalent cases for more than 12 months. The registry will include data from the visit at baseline, one year and two years. Socio-demographic, clinical, analytical variables, complications, comorbidities, association with other rheumatic diseases, hospital admissions, mortality and treatments will be collected. In addition, indices, scales and questionnaires of activity, muscle involvement, damage, disability, and quality of life will be determined. The recruitment period will be 23 months. The purpose is to obtain a cohort of 400 patients with IMM. Conclusions: Myo-Spain registry provides the opportunity to develop a cohort of incident and prevalent patients with IMM in Spain. Myo-Spain will be able to assess in detail the clinical characteristics of the disease at different times. The comprehensive information collected during the visits is expected to provide a broad source of data for future analysis. Sin financiación No data JCR 2021 0.311 SJR (2021) Q3, 44/61 Rheumatology No data IDR 2021 UEM

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results